Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (459)	2/24/2005 3:18:46 PM
From: CrazyPete	Read Replies (2) of 946

> If 75% of the dose of Xyotax excreted unchanged, that means > that you only have 25% of the remaining dose to reach that > threshold and elicit the therapeutic effect. I disagree with your logic. You're begging the question of whether the premise of conjugated taxol derivatives is valid. It seems to me that there are lots of variables here: (1) rates of transport of the drug to tumor and other tissues; (2) rates of clearance of the drug and its metabolites by excretory pathways; and (3) rates of metabolism of the original drug in the tumor and other tissues. You're saying you don't believe that Xyotax can be so specifically targeted to tumor tissue. But small changes in the rates of any of these steps can cause large changes in steady-state concentrations of the active drug metabolites in the tumor, and large changes in how the drug is excreted. The excretion of Xyotax is dominated by kinetics in tissues that are very different from the tumor, so I think you really can't conclude much from this one data point.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next